{"id":72780,"date":"2026-10-09T01:38:14","date_gmt":"2026-10-09T05:38:14","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-approves-roches-tecentriq-for-colon-cancer-eu-expands-russia-sanctions\/72780\/"},"modified":"2026-10-09T01:38:14","modified_gmt":"2026-10-09T05:38:14","slug":"fda-approves-roches-tecentriq-for-colon-cancer-eu-expands-russia-sanctions","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-approves-roches-tecentriq-for-colon-cancer-eu-expands-russia-sanctions\/72780\/","title":{"rendered":"FDA Approves Roche\u2019s Tecentriq for Colon Cancer; EU Expands Russia Sanctions"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> received <strong>FDA approval<\/strong> for <strong>Tecentriq<\/strong> as the first immunotherapy-based adjuvant treatment for a specific type of <strong>Stage III colon cancer<\/strong>, reducing recurrence risk by <strong>50%<\/strong>.<\/li>\n<li>The <strong>European Union<\/strong> has agreed to its largest-ever expansion of sanctions against Russia, blacklisting over <strong>1,600 individuals and entities<\/strong> primarily linked to the military-industrial complex.<\/li>\n<li><strong>Berlin<\/strong> and its EU partners extended restrictive measures against Russian &quot;hybrid&quot; activities until <strong>October 2027<\/strong>, targeting foreign information manipulation and interference.<\/li>\n<li>The <strong>FDA<\/strong> also cleared a subcutaneous formulation, <strong>Tecentriq Hybreza<\/strong>, providing more flexible administration options for adult and pediatric patients.<\/li>\n<\/ul>\n<h2>Roche Secures Landmark FDA Approval for Tecentriq in Colon Cancer<\/h2>\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong>&#39;s <strong>Tecentriq<\/strong> (atezolizumab) in combination with chemotherapy for the adjuvant treatment of patients with <strong>Stage III deficient DNA mismatch repair (dMMR) colon cancer<\/strong>. This milestone marks the <strong>twelfth indication<\/strong> for Tecentriq in the United States and establishes it as the first approved immunotherapy regimen for this patient population following surgery.<\/p>\n<p>The regulatory decision was supported by the <strong>Phase III ATOMIC study<\/strong>, which demonstrated that adding Tecentriq to standard chemotherapy reduced the risk of disease recurrence or death by <strong>50%<\/strong> compared to chemotherapy alone. Data showed a <strong>three-year disease-free survival rate of 86.4%<\/strong> for the combination group, versus <strong>76.6%<\/strong> for those receiving only chemotherapy. The approval also covers <strong>Tecentriq Hybreza<\/strong>, a subcutaneous formulation that can be administered in minutes, significantly reducing treatment time for patients.<\/p>\n<p><em>Market analysts suggest this approval addresses a critical unmet need, as approximately one in three patients with Stage III colon cancer currently experience recurrence within five years.<\/em> By targeting the specific biology of <strong>dMMR tumors<\/strong>, which are characterized by high mutation rates, <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> aims to set a new standard of care for early-stage colorectal oncology.<\/p>\n<h2>EU and Berlin Escalate Economic Pressure on Russia<\/h2>\n<p>In a coordinated move to intensify economic pressure, <strong>EU ambassadors<\/strong> in Brussels have agreed to a record-breaking expansion of the sanctions blacklist targeting the <strong>Russian economy<\/strong>. The new package adds <strong>743 individuals and 826 entities<\/strong>, bringing the total number of sanctioned names to nearly <strong>4,650<\/strong>. The listings focus heavily on Russia&#39;s <strong>military-industrial complex<\/strong>, with more than half of the new targets involved in <strong>missile production<\/strong>.<\/p>\n<p><strong>Berlin<\/strong> has been a key proponent of these measures, which also include a one-year extension of sanctions against Russia&#39;s &quot;hybrid&quot; activities until <strong>October 9, 2027<\/strong>. These restrictive measures target individuals and organizations responsible for <strong>Foreign Information Manipulation and Interference (FIMI)<\/strong> and other destabilizing actions across Europe. Sanctioned parties face immediate <strong>asset freezes<\/strong> and <strong>travel bans<\/strong>, while EU companies are prohibited from providing them with any financial resources.<\/p>\n<p><em>The timing of these sanctions coincides with reports of increased Russian hybrid operations targeting European infrastructure, including a recent drone incident at Leipzig airport.<\/em> While some regional German political factions have called for a lifting of sanctions, the federal government in <strong>Berlin<\/strong> remains committed to the EU&#39;s unified stance. Formal adoption of the expanded list is expected by EU foreign ministers on <strong>October 12, 2026<\/strong>, in Luxembourg.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Roche (RHHBY) received FDA approval for Tecentriq as the first immunotherapy-based adjuvant treatment for a specific type of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[5833,5979,6290,7590,8715,14359,19434,23026,23027],"class_list":["post-72780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-fda","tag-eu-sanctions","tag-fda-approval","tag-genentech","tag-oncology","tag-russia-economy","tag-roche-rhhby-stock-rhhby","tag-colon-cancer","tag-fimi"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/72780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=72780"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/72780\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=72780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=72780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=72780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}